Biotechnology · EmeryVille, California, United States
$12.76
-2.00% (-$0.26)2026-07-09
Smart-Money SignalNeutral · 50/100— Insiders are net sellers over 90 days (-$1.3M, 7 sales vs 5 buys)
Revenue$3.0M
Net Income-$68.8M
EPS$-1.01
Market Cap$667.0M
Price Performance
Historical data including institutional events
Company Profile
D
David Kirn
CEO & Executive Director
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The companyâs lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
- Founded
- 2013
- Employees
- 196
- Headquarters
- EmeryVille, California, United States
Peer ComparisonRevenue ($B)
▾Loading company sections...